<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="aspects, the â€œeasiestâ€� situation would correspond to a confirmed acute" exact="dengue fever," post="only requiring knowing when the patient should come back"/>
 <result pre="benefit. One specificity of CYD-TDV is that it possesses a" exact="yellow fever" post="17D (YF17D) backbone, and thus expresses NS antigens of"/>
 <result pre="fever 17D (YF17D) backbone, and thus expresses NS antigens of" exact="yellow fever" post="virus. Accordingly, while CYD-TDV is able to induce cellular"/>
 <result pre="range of cross-reactive antibody titers from a prior inactivated Japanese" exact="encephalitis" post="(JE) vaccination and then developing enhanced Yellow Fever (YF)"/>
 <result pre="to dengue viruses, such as Yellow fever (YF) or Japanese" exact="encephalitis" post="(JE) viruses. Information in this regard is more limited,"/>
 <result pre="interval of time by the YF17D vaccine on a Japanese" exact="encephalitis" post="chimeric vaccine (JE-CV, using as CYD-TDV a YF17D backbone),"/>
 <result pre="dengue riskNature201855771972310.1038/s41586-018-0157-429795354 40.NasveldP.E.MarjasonJ.BennettS.AaskovJ.ElliottS.McCarthyK.Kanesa-ThasanN.FeroldiE.ReidM.Concomitant or sequential administration of live attenuated Japanese" exact="encephalitis" post="chimeric virus vaccine and yellow fever 17D vaccine: Randomized"/>
 <result pre="administration of live attenuated Japanese encephalitis chimeric virus vaccine and" exact="yellow fever" post="17D vaccine: Randomized double-blind phase II evaluation of safety"/>
 <result pre="of safety and immunogenicityHum. Vaccines2010690691410.4161/hv.6.11.12854 41.LÃ³pezP.LanataC.F.ZambranoB.CortÃ©sM.AndradeT.AmemiyaI.TerronesC.GilA.I.VerasteguiH.MarquezV.et al.Immunogenicity and safety of" exact="yellow fever" post="vaccine (stamaril) when administered concomitantly with a tetravalent dengue"/>
 <result pre="adultsBMC Infect. Dis.20181847510.1186/s12879-018-3389-x30241510 43.GlassA.PolhemusM.WangD.JarmanR.G.ThomasS.J.FribergH.CurrierJ.R.BonaparteM.De La BarraR.PrinciottaM.F.et al.The effects of Japanese" exact="encephalitis" post="vaccine and accelerated dosing scheduling on the immunogenicity of"/>
 <result pre="and accelerated dosing scheduling on the immunogenicity of the chimeric" exact="yellow fever" post="derived tetravalent dengue vaccine: A phase II, randomized, open-label,"/>
</results>
